InVitae Corp (NYSE:NVTA) CFO Shelly D. Guyer sold 631 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $33.87, for a total value of $21,371.97. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shelly D. Guyer also recently made the following trade(s):

  • On Wednesday, August 19th, Shelly D. Guyer sold 18,956 shares of InVitae stock. The stock was sold at an average price of $32.10, for a total value of $608,487.60.
  • On Friday, July 17th, Shelly D. Guyer sold 12,000 shares of InVitae stock. The stock was sold at an average price of $33.16, for a total value of $397,920.00.

NYSE:NVTA opened at $39.01 on Wednesday. The stock has a fifty day moving average price of $32.11 and a 200-day moving average price of $22.48. The company has a market cap of $5.14 billion, a price-to-earnings ratio of -9.93 and a beta of 2.26. The company has a debt-to-equity ratio of 0.69, a quick ratio of 3.71 and a current ratio of 3.71. InVitae Corp has a fifty-two week low of $7.41 and a fifty-two week high of $39.94.

InVitae (NYSE:NVTA) last released its earnings results on Tuesday, August 4th. The medical research company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.15). The company had revenue of $46.20 million for the quarter, compared to the consensus estimate of $39.63 million. InVitae had a negative net margin of 182.73% and a negative return on equity of 77.82%. The business’s revenue was down 14.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.54) earnings per share. Research analysts predict that InVitae Corp will post -2.54 EPS for the current fiscal year.

NVTA has been the topic of a number of recent analyst reports. SVB Leerink decreased their target price on InVitae from $40.00 to $34.00 and set an “outperform” rating on the stock in a report on Wednesday, August 5th. Zacks Investment Research lowered InVitae from a “buy” rating to a “hold” rating in a report on Tuesday, July 14th. LADENBURG THALM/SH SH upped their price objective on InVitae from $31.25 to $37.25 and gave the company a “buy” rating in a report on Wednesday, August 5th. Benchmark lowered InVitae from a “buy” rating to a “hold” rating in a report on Wednesday, July 1st. Finally, Morgan Stanley initiated coverage on InVitae in a report on Wednesday, September 9th. They issued an “equal weight” rating and a $38.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. InVitae currently has an average rating of “Buy” and an average price target of $30.75.

Several large investors have recently added to or reduced their stakes in the company. Benjamin Edwards Inc. lifted its position in shares of InVitae by 46.7% during the 1st quarter. Benjamin Edwards Inc. now owns 2,217 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 706 shares during the period. Advisory Services Network LLC lifted its position in shares of InVitae by 8.4% during the 2nd quarter. Advisory Services Network LLC now owns 10,350 shares of the medical research company’s stock valued at $314,000 after acquiring an additional 800 shares during the period. Principal Financial Group Inc. lifted its position in shares of InVitae by 0.6% during the 1st quarter. Principal Financial Group Inc. now owns 136,624 shares of the medical research company’s stock valued at $1,868,000 after acquiring an additional 853 shares during the period. Captrust Financial Advisors bought a new stake in shares of InVitae during the 2nd quarter valued at $30,000. Finally, Kistler Tiffany Companies LLC bought a new stake in shares of InVitae during the 2nd quarter valued at $31,000. Hedge funds and other institutional investors own 98.58% of the company’s stock.

InVitae Company Profile

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.

Featured Story: Fundamental Analysis – How It Helps Investors

Insider Buying and Selling by Quarter for InVitae (NYSE:NVTA)

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.